Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Feature|Articles|October 8, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
A Steadying Trajectory: Biopharma Review and Outlook
Author(s)Peter Young
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Although the pace of innovation has been strong for both pharmaceutical and biotech companies, the financing, M&A and stock market developments in the first half of 2026 for organizations in both sectors have broken from past trends in certain categories, both positively and negatively. Many of these trends would seem not to make sense on the surface, but they are logical if you carefully examine the underlying drivers.
Related to this article
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement